Edition:
India

People: ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

56.45USD
9:06pm IST
Change (% chg)

$-0.21 (-0.37%)
Prev Close
$56.66
Open
$57.25
Day's High
$57.25
Day's Low
$55.96
Volume
78,007
Avg. Vol
414,410
52-wk High
$58.67
52-wk Low
$30.02

Stankovic, Srdjan 

Dr. Srdjan R. Stankovic M.D. serves as President of the Company. He has served as our President since November 2018. Dr. Stankovic previously served as our Executive Vice President, Head of Research and Development and has been with our company since November 2015. With a background in clinical and academic psychiatry, Dr. Stankovic brings over 20 years of executive level experience in drug development and clinical and medical affairs. Dr. Stankovic has built and led multidisciplinary teams for small molecules and biologics in therapeutic areas including neurology, psychiatry, oncology, cardiology and pain. He has led teams to achieve approvals of KEPPRA®, FENTORA®, TREANDA®, NUVIGIL® and ARISTADA™. Prior to joining our company, Dr. Stankovic served as Senior Vice President of Clinical Development and Medical Affairs at Alkermes plc. from 2013 to 2015. Prior to Alkermes, he held the position of Senior Vice President and Head of Global Clinical Development for Teva Pharmaceuticals Ltd. He was appointed to this role following Teva’s acquisition of Cephalon, Inc. where he served as Senior Vice President, Worldwide Clinical Research. Dr. Stankovic also served as Senior Vice President, Medical Affairs and Clinical Development CNS at Forest Laboratories, Inc. and held executive positions in research and development at Neurogen Corporation, Johnson and Johnson, and UCB. Dr. Stankovic received his M.D. from the University of Belgrade and holds a Master of Science in public health from the University of Alabama at Birmingham.

Basic Compensation

Total Annual Compensation, USD 693,563
Restricted Stock Award, USD 1,932,330
Long-Term Incentive Plans, USD --
All Other, USD 2,462,380
Fiscal Year Total, USD 5,088,270

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stephen Biggar

319,959

Srdjan Stankovic

5,088,270

Stephen Davis

7,631,250

Elena Ridloff

1,990,870

Austin Kim

1,906,130

Gudarz Davar

--
As Of  31 Dec 2019